Definium Therapeutics Expands DT120 ODT Program into Phase 3 PTSD Study, Confirms Multiple Near-Term Data Readouts

summarizeSummary

Definium Therapeutics reported Q1 2026 financial results, including a widened net loss, but highlighted significant clinical progress with its DT120 ODT program, including the expansion into a Phase 3 PTSD study and upcoming topline data readouts for MDD and GAD.

check_boxKey Events

• Q1 2026 Financial Results

  Definium Therapeutics reported a net loss of $77.1 million for Q1 2026, widening from $23.3 million in Q1 2025, driven by increased R&D and G&A expenses.

• Extended Cash Runway

  The company holds $373.4 million in cash, cash equivalents, and investments as of March 31, 2026, projected to fund operations into 2028.

• DT120 ODT Program Expansion

  Definium Therapeutics is expanding its DT120 ODT clinical development program into Post-Traumatic Stress Disorder (PTSD) with plans to initiate a Phase 3 Haven study in 2027.

• Multiple Phase 3 Data Readouts Imminent

  Enrollment is complete for the Emerge (MDD) and Voyage (GAD) studies, with topline data expected in late 2Q 2026 and early 3Q 2026, respectively. Panorama (GAD) enrollment is also complete, with data expected in late 3Q 2026.

auto_awesomeAnalysis

This 8-K, filed concurrently with the Q1 2026 10-Q, provides a comprehensive operational update for Definium Therapeutics. While the company reported a widened net loss for Q1 2026, it also announced a significant expansion of its lead candidate, DT120 ODT, into a Phase 3 study for Post-Traumatic Stress Disorder (PTSD), with initiation expected in 2027. Additionally, the company confirmed the completion of enrollment for two Phase 3 studies (Emerge for MDD and Voyage for GAD) and nearing completion for another (Panorama for GAD), with topline data readouts anticipated in the coming months. The company also reported a strong cash position of $373.4 million, providing an operational runway into 2028. These clinical milestones and pipeline expansion are critical for a late-stage biopharmaceutical company, demonstrating significant progress and future catalysts, which largely balance the negative financial results.